Recursion Pharmaceuticals, Inc. (RXRX)
3.60
-0.15
(-4.00%)
USD |
NASDAQ |
Apr 16, 16:00
3.61
+0.01
(+0.28%)
After-Hours: 20:00
Recursion Pharmaceuticals Research and Development Expense (Quarterly) : 83.34M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Intellia Therapeutics, Inc. | 86.27M |
| Tango Therapeutics, Inc. | 31.62M |
| Geron Corp. | 15.83M |
| Ionis Pharmaceuticals, Inc. | 279.36M |
| Quince Therapeutics, Inc. | 12.60M |